)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SoftOx Solutions
SoftOx Solutions (SOFTX) investor relations material
SoftOx Solutions Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary23 Sep, 2026
Executive summary
Transitioned from clinical preparation to active execution in both SIS-02 and SIS-03 programs, achieving key milestones including completion of SIS-03 dose escalation and initiation of proof-of-concept phase in patients with chronic airway infections.
SIS-02 Phase 1 biodefense study began dosing healthy volunteers in June 2026, with readout expected H1 2027.
Focus remains on advancing clinical programs to value inflection points and preparing for future financing and partnerships.
Financial highlights
H1 2026 operating revenue NOK 5.8m, down from NOK 7.5m H1 2025, reflecting EDF project milestone timing.
Pre-tax loss widened to NOK 13.6m (H1 2025: NOK 1.4m loss) due to increased R&D and clinical activity.
Cash position at end H1 2026 was NOK 21.4m, up from NOK 19.8m at 2025 year-end.
Total equity increased to NOK 29.6m (31.12.25: NOK 23.0m) following equity raises.
H1 2026 saw NOK 20.1m raised via Long State placements and a further NOK 5.75m in July 2026 direct placement.
Outlook and guidance
SIS-03 proof-of-concept phase in chronic airway infections is underway, with topline results expected H1 2027.
SIS-02 Phase 1 biodefense study is ongoing, with readout also expected H1 2027.
Continued disciplined capital allocation and lean operations planned through key milestones.
Board confirms sufficient flexibility through existing financing and cash to support near-term operations, but continued access to capital remains important.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SoftOx Solutions
- Clinical execution advanced, R&D spending rose, and key milestones set up value inflection.SOFTX
Q1 2026 - Sharpened clinical focus and cost control drove improved results and pipeline progress.SOFTXQ4 2025
- Losses narrowed, liquidity improved, and clinical trials for inhaled therapeutics advance.SOFTXQ3 2025
- Losses narrowed and clinical trial plans advanced, supported by new funding and cost controls.SOFTXQ2 2025
- Phase IIa CF trial targets major value inflection, with strong market and partnership prospects.SOFTXInvestor update
- Q1 profit achieved after restructuring, with clinical trials and funding efforts underway.SOFTXQ1 2025
- Q3 loss deepened amid restructuring, with new funding and a strategic spinout planned.SOFTXQ3 2024
- Debt-free, lean team targets pivotal Phase II VAP trial and seeks NOK 60–80m funding.SOFTXInvestor update
- Refocused on inhalation therapeutics, improved liquidity, and advanced clinical trial plans.SOFTXQ4 2024
Next SoftOx Solutions earnings date
Q3 202625 Nov, 2026
SoftOx Solutions
Next SoftOx Solutions earnings date
Q3 202625 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
SoftOx Solutions operates as a biotech company. The company focuses on the development of medical devices for diagnostics and treatment of tissue injury and other diseases. Its products include SoftOx Endo, which is used to treat tissue deterioration in the esophagus; and SoftOx Burn, which is used to prevent scarring following burn injuries.